Literature DB >> 20133237

Liver transplantation for acute intermittent porphyria: a viable treatment?

Faisal S Dar1, Koji Asai, Ali Raza Haque, Thomas Cherian, Mohamed Rela, Nigel Heaton.   

Abstract

BACKGROUND: Acute intermittent porphyria (AIP) is the most common hepatic porphyria. Its clinical presentation includes severe disabling and life-threatening neurovisceral symptoms and acute psychiatric symptoms. These symptoms result from the overproduction and accumulation of porphyrin precursors, 5-aminoleuvulinic acid (ALA) and porphobilinogen (PBG). The effect of medical treatment is transient and is not effective once irreversible neurological damage has occurred. Liver transplantation (LT) replaces hepatic enzymes and can restore normal excretion of ALA and PBG and prevent acute attacks.
METHOD: Two cases of LT for AIP were identified retrospectively from a prospectively maintained LT database. RESULT: LT was successful with resolution of AIP in two patients who suffered from repeated acute attacks.
CONCLUSION: LT can correct the underlying metabolic abnormality in AIP and improves quality of life significantly.

Entities:  

Mesh:

Year:  2010        PMID: 20133237

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  8 in total

1.  Marked geographic aggregation of acute intermittent porphyria families carrying mutation Q180X in Venezuelan populations, with description of further mutations.

Authors:  Irene Paradisi; Sergio Arias
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

2.  Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.

Authors:  Makiko Yasuda; Angelika L Erwin; Lawrence U Liu; Manisha Balwani; Brenden Chen; Senkottuvelan Kadirvel; Lin Gan; M Isabel Fiel; Ronald E Gordon; Chunli Yu; Sonia Clavero; Antonios Arvelakis; Hetanshi Naik; L David Martin; John D Phillips; Karl E Anderson; Vaithamanithi M Sadagoparamanujam; Sander S Florman; Robert J Desnick
Journal:  Mol Med       Date:  2015-06-05       Impact factor: 6.354

3.  Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria.

Authors:  Pyoung-Jae Park; Shin Hwang; Young-Il Choi; Young-Dong Yu; Gil-Chun Park; Sung-Won Jung; Sam-Youl Yoon; Gi-Won Song; Tae-Yong Ha; Sung-Gyu Lee
Journal:  Clin Mol Hepatol       Date:  2012-12-21

4.  Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis.

Authors:  Joanna K Dowman; Bridget K Gunson; Darius F Mirza; Simon R Bramhall; Mike N Badminton; Philip N Newsome
Journal:  Liver Transpl       Date:  2012-02       Impact factor: 5.799

5.  Liver Transplantation because of Acute Liver Failure due to Heme Arginate Overdose in a Patient with Acute Intermittent Porphyria.

Authors:  Pascal Frei; Elisabeth I Minder; Natascia Corti; Beat Muellhaupt; Andreas Geier; Heiner Adams; Jean-Paul Dutertre; Alain Rudiger; Philipp Dutkowski; Marco Maggiorini; Christoph C Ganter
Journal:  Case Rep Gastroenterol       Date:  2012-04-19

Review 6.  Clinically important features of porphyrin and heme metabolism and the porphyrias.

Authors:  Siddesh Besur; Wehong Hou; Paul Schmeltzer; Herbert L Bonkovsky
Journal:  Metabolites       Date:  2014-11-03

7.  A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.

Authors:  Helene J Bustad; Karen Toska; Caroline Schmitt; Marta Vorland; Lars Skjærven; Juha P Kallio; Sylvie Simonin; Philippe Letteron; Jarl Underhaug; Sverre Sandberg; Aurora Martinez
Journal:  Mol Ther       Date:  2019-12-04       Impact factor: 11.454

Review 8.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.